KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Emergent BioSolutions (EBS) Short-Term Debt repayments (2019 - 2024)

Emergent BioSolutions has reported Short-Term Debt repayments over the past 4 years, most recently at $222.7 million for Q3 2024.

For Q3 2024, Short-Term Debt repayments rose 471.03% year-over-year to $222.7 million; the TTM value through Jun 2025 reached $222.7 million, up 97.96%, while the annual FY2024 figure was $284.2 million, 28.74% down from the prior year.
Short-Term Debt repayments for Q3 2024 was $222.7 million at Emergent BioSolutions, up from $56.5 million in the prior quarter.
Over five years, Short-Term Debt repayments peaked at $353.0 million in Q3 2020 and troughed at $5.0 million in Q1 2024.
A 3-year average of $132.0 million and a median of $47.8 million in 2023 define the central range for Short-Term Debt repayments.
Biggest five-year swings in Short-Term Debt repayments: skyrocketed 2253.33% in 2020 and later tumbled 83.76% in 2024.
Year by year, Short-Term Debt repayments stood at $353.0 million in 2020, then tumbled by 96.6% to $12.0 million in 2023, then skyrocketed by 1755.83% to $222.7 million in 2024.
Business Quant data shows Short-Term Debt repayments for EBS at $222.7 million in Q3 2024, $56.5 million in Q2 2024, and $5.0 million in Q1 2024.